# US 2026/0097072 A1 · Formulations of ammonium chloride to support human natural defense against viruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097072 A1
- Document ID: US20260097072A1
- Status: Published application
- Kind: A1
- Application number: 19/349,399
- Filed: 2025-10-03
- Published: 2026-04-09
- Earliest claimed: 2024-10-03
- Inventors: Nikolaos Tsirikos-Karapanos; Nikolaos Drakoulis
- Web page: https://patentgrep.com/patent/US20260097072A1

## CPC

- A61K 33/20: Elemental chlorine; Inorganic compounds releasing chlorine
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/5005: {Wall or coating material}
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH4Cl), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.

## Claims

### Claim 1

A formulation for militating against a clinical manifestation of infection by a virus in a subject, the formulation comprising:
a lysosomotropic agent including ammonium chloride in an amount from about 10 mg to about 2,000 mg;
wherein the formulation is configured in a unit dosage form and includes an enteric coating configured for oral administration that provides a sustained release of the ammonium chloride.

### Claim 2 (depends on 1)

The formulation according to claim 1, wherein the formulation has a dissolution profile from 4 hours to 24 hours of full release of ammonium chloride.

### Claim 3 (depends on 2)

The formulation according to claim 2, wherein the dissolution profile is determined by U.S. Pharmacopeial Convention Monograph USP <711>.

### Claim 4 (depends on 1)

The formulation according to claim 1, further comprising a secosteroid.

### Claim 5 (depends on 4)

The formulation according to claim 4, wherein the secosteroid includes vitamin D.

### Claim 6 (depends on 1)

The formulation according to claim 1, wherein the formulation includes:
the ammonium chloride at 250-500 mg;
vitamin D; and
an excipient including a member selected from a group consisting of steric acid, acetyl alcohol, stearyl alcohol, polyvinylpyrrolidone, magnesium stearate, and combinations thereof.

### Claim 7 (depends on 6)

The formulation according to claim 6, wherein the formulation includes:
the ammonium chloride at 250-1,500 mg;
the vitamin D at 1,000-4,000 IU; and
the excipient including steric acid, acetyl alcohol, stearyl alcohol, polyvinylpyrrolidone, and magnesium stearate.

### Claim 8 (depends on 1)

The formulation according to claim 1, wherein the lysosomotropic agent is in an amount effective to reduce intracellular viral load at 24 hours post-infection.

### Claim 9 (depends on 8)

The formulation according to claim 8, wherein the lysosomotropic agent is in an amount effective to reduce intracellular viral load from 24 hours post-infection up to 72 hours post-infection.

### Claim 10 (depends on 9)

The formulation according to claim 9, wherein the lysosomotropic agent is in an amount effective to increase a threshold cycle for detecting intracellular viral load by RT-PCR at 72 hours post-infection by at least 25% for SARS-CoV-2.

### Claim 11 (depends on 9)

The formulation according to claim 9, wherein the lysosomotropic agent is in an amount effective to increase a threshold cycle for detecting intracellular viral load by RT-PCR at 72 hours post-infection by at least 50% to 100% for influenza-A.

### Claim 12 (depends on 1)

The formulation according to claim 1, wherein:
the formulation has a dissolution profile from 4 hours to 12 hours of full release of ammonium chloride and the dissolution profile is determined by U.S. Pharmacopeial Convention Monograph USP <711>;
the formulation includes the ammonium chloride at 250-1,500 mg, vitamin D, and an excipient including a member selected from a group consisting of steric acid, acetyl alcohol, stearyl alcohol, polyvinylpyrrolidone, magnesium stearate, and combinations thereof; and
the lysosomotropic agent is in an amount effective to reduce intracellular viral load at 24 hours post-infection.

### Claim 13

A method of militating against a clinical manifestation of infection by a virus in a subject, the method comprising:
administering a formulation to the subject, the formulation including a lysosomotropic agent having ammonium chloride in an amount from about 10 mg to about 2,000 mg, the formulation configured in a unit dosage form, and the formulation having an enteric coating configured for oral administration that provides a sustained release of the ammonium chloride;
monitoring the subject for at least one of alkalosis and acidosis, wherein the monitoring includes measuring a blood pH of the subject;
selectively adjusting the administering of the formulation to the subject based on the monitoring so that the subject is not exhibiting alkalosis and is not exhibiting acidosis, wherein the selectively adjusting includes adjusting the administering of the formulation to the subject until the blood pH of the subject is between about 7.35 and about 7.45; and
continuing the administering of the formulation over a period of at least 24 hours to reduce intracellular viral load at 24 hours post-infection.

### Claim 14 (depends on 13)

The method according to claim 13, wherein continuing the administering of the formulation includes continuing administration of the formulation over a period of 72 hours to reduce intracellular viral load at 72 hours post-infection.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the formulation has a dissolution profile from 4 hours to 24 hours of full release of ammonium chloride.

### Claim 16 (depends on 13)

The method according to claim 13, wherein the formulation includes:
the ammonium chloride at 250-500 mg;
vitamin D; and
an excipient including a member selected from a group consisting of steric acid, acetyl alcohol, stearyl alcohol, polyvinylpyrrolidone, magnesium stearate, and combinations thereof.

### Claim 17 (depends on 13)

The method according to claim 13, wherein the virus includes SARS-CoV-2 and the lysosomotropic agent is in an amount effective to increase a threshold cycle for detecting intracellular viral load by RT-PCR at 72 hours post-infection by at least 10% to 25% for SARS-CoV-2.

### Claim 18 (depends on 13)

The method according to claim 13, wherein the virus includes influenza-A or influenza-B and the lysosomotropic agent is in an amount effective to increase a threshold cycle for detecting intracellular viral load by RT-PCR at 72 hours post-infection by at least 50% to 100% for influenza-A or influenza-B.

### Claim 19 (depends on 13)

The method according to claim 13, further comprising continuing the administration of the formulation to the subject until the virus cannot be detected in the subject.

### Claim 20 (depends on 13)

The method according to claim 13, further comprising continuing the administration of the formulation to the subject until an antibody to the virus is detected in the subject.
